davamotecan pegadexamer (EP0057) / Lumos Pharma, Ellipses Pharma  >>  Phase 2
Welcome,         Profile    Billing    Logout  

13 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
davamotecan pegadexamer (EP0057) / Ellipses Pharma
NCT00753740: Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.

Withdrawn
2
0
US
IT-101 (12mg/m2/dose), IT-101 (15mg/m2/dose), 5% Dextrose (Placebo)
NewLink Genetics Corporation
Cancer, Ovarian Cancer, Solid Tumor
10/09
05/10
NCT01565421: Efficacy Study of Maintenance Therapy for Ovarian Cancer Patients

Withdrawn
2
0
US
IT-101, 5% Dextrose (Placebo)
NewLink Genetics Corporation
Cancer, Ovarian Cancer, Solid Tumor
10/09
05/10
NCT01380769: A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer

Checkmark P2 NSCLC data
Mar 2015 - Mar 2015: P2 NSCLC data
Checkmark
Mar 2013 - Mar 2013: 
Completed
2
157
RoW
CRLX101, NLG207, Best Supportive Care
NewLink Genetics Corporation
Non-Small Cell Lung Cancer
02/13
10/14
NCT01612546: Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery

Completed
2
10
US
cyclodextrin-based polymer-camptothecin CRLX101, CRLX101, cyclodextrin-based polymer-camptothecin IT-101, IT-101, Laboratory biomarker analysis, Pharmacological studies
City of Hope Medical Center, National Cancer Institute (NCI)
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Squamous Cell Carcinoma of the Esophagus, Stage IIIB Esophageal Cancer, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer
01/15
01/15
NCT01803269: Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer

Terminated
2
29
US
topotecan hydrochloride, hycamptamine, Hycamtin, SKF S-104864-A, TOPO, cyclodextrin-based polymer-camptothecin CRLX101, CRLX101, cyclodextrin-based polymer-camptothecin IT-101, IT-101
University of Chicago, National Cancer Institute (NCI)
Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
03/16
03/16
NCT02187302: CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)

Checkmark In combination with Avastin for advanced RCC
Feb 2020 - Feb 2020: In combination with Avastin for advanced RCC
Checkmark Randomized data (PFS & ORR endpoints) of CRLX101 in combination with Avastin in RCC
Aug 2016 - Aug 2016: Randomized data (PFS & ORR endpoints) of CRLX101 in combination with Avastin in RCC
Completed
2
115
US, RoW
CRLX101, NLG207, Bevacizumab, Avastin, Standard of Care (Investigator Choice), sorafenib (Nexavar), sunitinib (Sutent), axitinib (Inlyta), pazopanib (Votrient), bevacizumab (Avastin),, everolimus (Afinitor), Other
NewLink Genetics Corporation
Metastatic Renal Cell Carcinoma
07/16
01/17
NCT01652079: CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer

Hourglass Jul 2016 - Dec 2016 : Interim data of CRLX101 in combination with Avastin in relapsed ovarian cancer
Checkmark CRLX101 + Avastin in platinum-resistant ovarian cancer
Feb 2016 - Feb 2016: CRLX101 + Avastin in platinum-resistant ovarian cancer
Checkmark Relapsed ovarian cancer
Jun 2015 - Jun 2015: Relapsed ovarian cancer
More
Completed
2
63
US
CRLX101
Massachusetts General Hospital
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
03/18
03/18
NCT03531827: Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

Terminated
2
4
US
enzalutamide, Xtandi, CRLX101, IT-101
National Cancer Institute (NCI)
Metastatic Castration Resistant Prostate Cancer, Prostate Neoplasms
05/21
06/21
NCT04669002 / 2020-003083-98: EP0057 in Combination With Olaparib in Advanced Ovarian Cancer

Completed
2
34
Europe, US
EP0057, Olaparib tablets, Lynparza
Ellipses Pharma
Ovarian Cancer
02/23
05/23
NCT05411679: EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer

Withdrawn
2
115
RoW
EP0057, Olaparib tablets
Ellipses Pharma
Gastric Cancer, Small-cell Lung Cancer
08/24
12/24
NCT00333502: Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors

Checkmark
Feb 2013 - Feb 2013: 
Completed
1b/2a
62
US
Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer, NLG207, IT-101
NewLink Genetics Corporation
Cancer, Solid Tumor
11/11
04/12
NCT02010567: Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer

Checkmark For advanced rectal cancer in combination with chemoradiotherapy
Jul 2016 - Dec 2016: For advanced rectal cancer in combination with chemoradiotherapy
Checkmark Efficacy data of non metastatic rectal cancer
Jun 2015 - Jun 2015: Efficacy data of non metastatic rectal cancer
Terminated
1/2
32
US
CRLX101, Capecitabine, Xeloda, Radiotherapy, Intensity Modulated Radiation Therapy, IMRT, Surgery, Resection, Surgical resection
UNC Lineberger Comprehensive Cancer Center, Cerulean Pharma Inc.
Rectal Cancer
09/16
06/19
NCT02389985: A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Hourglass Jan 2017 - Dec 2017 : data from P1b/2 trial in combination with weekly paclitaxel in platinum- resistant ovarian cancer
Hourglass Oct 2016 - Oct 2016 : From the second group of patients of P1b trial for CRLX101 in combination with weekly paclitaxel in ovarian cancer at ESMO
Checkmark Enrollment initiation for P2 trial for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer
Jul 2016 - Jul 2016: Enrollment initiation for P2 trial for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer
Checkmark Enrollment initiation for P2 trial for relapsed ovarian cancer in combination with paclitaxel
More
Terminated
1/2
30
US
CRLX101, NLG207, Paclitaxel, Taxol
NewLink Genetics Corporation
Ovarian Cancer
06/18
10/18

Download Options